In the following you get an overview about the latest press reports:

FDA publish DMF Number for synthetic CBD (November, 2008)
Drug Master File (DMF) No 22103 for Synthetic Cannabidiol became active in the United States November 2008.
In a joint venture between THC Pharm and STI Pharmaceuticals Ltd the DMF submission to the FDA is intended to open new opportunities for researchers in the US and Europe wishing to advance into human clinical trials.
CBD is currently under investigation for its medical potential in a range of indications such as Parkinson's disease, Diabetes and Cancer.
 
THC Pharm welcomes first license for cannabis based medication for multiple sklerosis (May, 3rd, 2005)
more
 
THC Pharm obtains patent for improved Dronabinol production process (March, 10th,2005)
Production of synthetic cannabinoids planned for 2005
more
 
THC Pharm launches its new website (Oct, 2nd, 2003)
more
 
THC Pharm aims to obtain a license for a Cannabis medication (June,30th, 2003)
Five years Dronabinol from THC Pharm – price reduction from 1st of July
 
THC Pharm sees growing market for cannabis as medicine (May, 30th, 2002)
 
Revolution in pain therapy by possibility of inhalation (March, 13th, 2001)